antivir
activ
four
schiff
base
aminohydroxyguanidin
design
test
human
adenoviru
type
cell
plaqu
reduct
viru
yield
reduct
method
compound
tosyl
gave
best
therapeut
indic
respect
pretreat
cell
ml
affect
adsorpt
penetr
viru
ultrastructur
studi
show
drug
treat
infect
cell
unidentifi
irregular
shape
electron
dens
structur
might
drug
alter
viral
macromolecul
assembl
complet
infecti
viru
particl
sinc
compound
metal
chelat
properti
antivir
activ
may
involv
earli
ia
eia
gene
encod
viral
protein
amino
acid
zinc
finger
moieti
requir
transactiv
activ
year
recent
year
report
sever
occasion
fatal
adenovir
infect
may
occur
infant
young
children
uhnoo
et
al
chiba
et
al
yolken
et
al
immunocompromis
patient
shield
et
al
stalder
et
al
zahradnik
et
al
ocular
adenoviru
infect
occur
worldwid
frequent
result
epidem
commun
medic
facil
epidem
keratoconjunct
gener
caus
adenoviru
type
frequent
occur
highli
infecti
diseas
ford
et
al
although
hpmpc
hpmpa
gmp
report
good
antiadenovir
activ
baba
et
al
gordon
et
al
current
exist
antivir
treatment
known
prevent
lessen
sequela
adenovirusinduc
diseas
primari
eye
involv
likewis
treatment
exist
protect
spread
viru
second
eye
individu
recent
report
gordon
et
al
tsai
et
al
describ
anim
model
evalu
effect
potent
experiment
antivir
drug
ocular
adenoviru
infect
hydroxyurea
hydroxyguanidin
thiosemicarbazon
inhibit
ribonucleotid
reductas
report
antitumor
well
antivir
activ
krakoff
adamson
sartorelli
et
al
carter
levinson
et
al
substitut
schiff
base
aminohydroxyguanidin
combin
structur
featur
compound
fig
seri
aminohydroxyguanidin
compound
synthes
test
biolog
activ
laboratori
tai
et
al
tang
et
al
wang
et
al
koneru
antivir
activ
aminohydroxyguanidin
report
rou
sarcoma
viru
tang
et
al
coronaviru
wang
et
al
herp
simplex
viru
type
lien
et
al
contribut
differ
moieti
molecul
activ
agent
discuss
lien
et
al
lien
et
al
lien
et
al
studi
report
vitro
studi
antivir
activ
schiff
base
aminohydroxyguanidin
adenoviru
type
adenoviru
type
common
serotyp
infect
ocular
respiratori
gastrointestin
system
type
one
common
serotyp
infect
eye
frequent
caus
epidem
keratoconjunct
human
lung
tumor
cell
american
type
cultur
collect
atcc
use
host
cell
previous
describ
tsai
et
al
briefli
cell
grown
contain
heatinactiv
fetal
bovin
serum
fb
plaqu
assay
concentr
fb
reduc
adenoviru
type
shenk
purdu
univers
type
atcc
stock
prepar
inocul
monolay
multipl
infect
adsorpt
room
temperatur
incub
cytopath
effect
cpe
involv
approxim
cell
monolay
cultur
freezethaw
sonic
centrifug
titer
plaqu
assay
viru
store
aliquot
use
plaqu
assay
method
cell
grow
tissu
cultur
plate
inocul
dilut
sampl
well
per
dilut
adsorpt
period
inoculum
remov
monolay
wash
hank
balanc
salt
solut
hbss
lxe
without
ca
mg
remov
unadsorb
viru
overlaid
ham
contain
methylcellulos
monolay
examin
microscop
plaqu
appear
clearli
day
cultur
fix
acet
acid
methanol
rins
water
stain
crystal
violet
methanol
count
structur
formula
substitut
schiff
base
aminohydroxyguanidin
tosyl
test
shown
fig
synthesi
chemic
properti
compound
report
hui
et
al
unpublish
structur
schiff
base
tosyl
type
rnnhc
nh
nhoh
r
group
substitut
follow
compound
compound
compound
methylen
compound
hexyloxi
benzyliden
compound
compound
compound
compound
compound
compound
methylen
initi
dissolv
dimethyl
sulfoxid
dmso
dilut
mainten
medium
use
final
highest
concentr
dmso
use
cultur
compound
test
necessari
addit
drug
concentr
also
test
ie
ultrastructur
studi
perform
confluent
monolay
cell
tissu
cultur
plate
wash
hbss
expos
variou
concentr
compound
well
use
concentr
cell
examin
daili
light
microscopi
day
cytotox
record
abnorm
morpholog
chang
observ
effect
compound
cell
prolifer
also
evalu
quantit
cell
confluent
triplic
monolay
wash
hbss
expos
variou
concentr
compound
h
incub
monolay
dispers
individu
cell
trypsin
suspend
ham
fb
quantit
coulter
counter
express
use
drug
toxic
concentr
compound
reduc
cell
count
treat
cell
compar
untreat
cell
eg
cell
pm
viru
yield
reduct
assay
cell
grown
plate
growth
medium
incub
cell
cultur
becam
approxim
confluent
growth
medium
remov
cell
infect
viru
multipl
infect
moi
plaqueform
unit
pfu
per
cell
h
adsorpt
room
temperatur
inoculum
remov
monolay
wash
hbss
mainten
medium
contain
variou
concentr
compound
ad
control
cell
drug
viru
drug
control
viru
viru
control
drug
includ
plate
cpe
observ
viru
control
h
sampl
freezethaw
sonic
centrifug
titer
plaqu
assay
describ
b
plaqu
reduct
assay
confluent
cell
grown
tissu
cultur
plate
infect
approxim
pfu
viru
stock
per
well
one
hour
viru
adsorpt
room
temperatur
overlay
medium
contain
methylcellulos
without
test
compound
rang
ad
infect
cell
monolay
day
incub
monolay
fix
stain
describ
plaqu
count
data
plot
antivir
concentr
versu
number
plaqu
inhibitori
dose
antivir
determin
graph
effect
drug
treatment
viru
inocul
cell
assess
plaqu
reduct
method
follow
uninfect
confluent
monolay
preincub
drug
h
inocul
treat
drug
postinocul
ii
monolay
preincub
drug
h
inocul
receiv
drug
inocul
iii
receiv
drug
treatment
inocul
cell
cultur
medium
given
time
point
ii
inocul
inocul
monolay
incub
six
day
fix
stain
plaqu
count
effect
compound
cell
studi
ultrathin
section
transmiss
electron
microscopi
pm
ad
inocul
monolay
onehour
viru
adsorpt
pfucel
incub
h
fix
halfstrength
karnovski
solut
process
electron
microscopi
studi
ultrathin
section
stain
uranyl
acet
lead
citrat
examin
zeiss
model
aei
west
germani
transmiss
electron
microscop
kv
three
set
control
studi
similar
fashion
ie
cell
control
viru
drug
viru
control
drug
drug
control
viru
drug
concentrationrespons
curv
compound
present
fig
compound
prevent
plaqu
format
attm
concentr
valu
pm
respect
similar
plaqu
reduct
data
observ
studi
ie
valu
respect
base
upon
cytotox
curv
fig
present
cell
growth
reduct
appear
much
less
toxic
activ
compound
test
cytotox
curv
lkll
end
studi
termin
concentr
concentr
beyond
point
caus
obviou
morpholog
damag
host
cell
four
potent
antivir
compound
desir
therapeut
indic
unpublish
data
cell
select
ultrastructur
studi
im
gave
signific
viral
inhibit
reduc
viru
yield
two
log
unit
h
postinocul
fig
howev
viru
inhibit
less
h
postinocul
sinc
h
sensit
point
measur
antivir
activ
viru
yield
assay
lkll
harvest
h
postinocul
rel
antivir
activ
shown
fig
reduc
viru
yield
significantli
least
potent
cell
pretreat
cell
ie
follow
drug
remov
prior
inocul
appear
interfer
viru
adsorpt
step
viral
replic
plaqu
reduct
observ
tabl
pretreat
enhanc
significantli
antivir
activ
postinocul
treatment
contain
medium
ad
inocul
cell
hour
viru
adsorpt
reduct
plaqu
observ
rang
concentr
morpholog
cell
inocul
without
appear
ident
thinsect
normal
cell
magnif
shown
fig
fig
present
cell
cluster
viru
particl
h
postinocul
fig
cell
treat
viru
particl
present
unidentifi
irregular
shape
electron
dens
structur
see
arrow
fig
uniqu
drug
treat
viru
infect
cell
structur
never
observ
either
treat
normal
cell
untreat
infect
cell
struc
ture
could
drug
alter
viral
antigen
could
assembl
complet
infecti
viru
particl
among
schiff
base
aminohydroxyguanidin
test
report
elsewher
hui
et
al
unpublish
result
promis
antiadenovir
agent
consist
gave
posit
antivir
activ
plaqu
reduct
viru
yield
reduct
assay
method
show
least
cytotox
toward
host
cell
among
activ
compound
ie
lkll
potent
antivir
activ
minim
cytotox
suggest
may
clinic
use
adenoviru
infect
ml
rang
unreport
vitro
studi
show
highli
penetr
conjunctiva
cornea
give
target
treatment
methodolog
use
assess
drug
effect
cell
morpholog
viabil
growth
mani
disadvantag
subject
lack
sen
fig
thinsect
cell
x
viru
particl
appear
crystallin
lattic
insid
nucleu
sitiv
may
allow
underestim
toxic
howev
futur
studi
promis
antivir
compound
involv
detail
stringent
cytotox
test
one
reason
focus
onto
screen
schiff
base
aminohydroxyguanidin
adenovirus
know
metal
chelat
capabl
schiff
base
aminohydroxyguanidin
import
zinc
ion
function
gene
product
gene
encod
protein
amino
acid
zinc
finger
moieti
requir
transactiv
activ
culp
et
al
express
requir
transcript
earli
viral
mrna
propos
transactiv
abil
amino
acid
protein
may
interf
zinc
chelat
aminohydroxyguanidin
adenovirus
virus
schiff
base
aminohydroxyguanidin
act
shown
antivir
activ
rou
sarcoma
viru
tai
et
al
tang
et
al
coronaviru
wang
et
al
herp
simplex
viru
lien
et
al
tabl
summar
antitumor
activ
compound
tai
et
al
tang
et
al
koneru
well
inhibit
ribonucleotid
reductas
activ
cori
et
al
ribonucleotid
reductas
catalyz
key
step
synthesi
fig
thinsect
cell
treat
mli
viru
particl
scatter
insid
nucleu
along
unidentifi
irregular
structur
see
arrow
materi
could
modifi
viral
macromolecul
could
assembl
complet
infecti
viru
particl
deoxyribonucleotid
precursor
dna
synthesi
possibl
antivir
activ
relat
either
interfer
transactiv
abil
amino
acid
protein
inhibit
ribonucleotid
reductas
compound
antiadenovir
activ
although
shown
tai
et
al
antitumor
activ
cultur
cell
icso
leukem
cell
growth
pm
respect
tai
et
al
tang
et
al
report
cell
growth
respect
shown
potent
antiadenovir
activ
present
studi
shown
inhibit
addit
shown
inhibit
ribonucleotid
reductas
activ
pm
respect
antiadenovir
activ
final
lk
seri
compound
low
antiadenovir
activ
potent
valu
antileukem
activ
ccrfcemo
cell
line
similar
respect
koneru
appear
obviou
correl
antiadenovir
antitumor
activ
schiff
base
aminohydroxyguanidin
ribonucleotid
reductas
inhibit
activ
inhibit
viral
replic
h
may
due
sever
factor
first
kinet
viral
replic
may
slow
drugtreat
cultur
field
case
appar
inhibit
yield
function
time
assay
infect
left
suffici
long
period
inhibit
yield
would
observ
secondli
antivir
drug
stabil
yet
establish
unstabl
compound
might
less
antivir
activ
extend
incub
period
multipl
viru
growth
cycl
eg
h
postinocul
thirdli
develop
drugresist
could
least
partial
respons
failur
inhibit
viru
growth
h
order
investig
pass
four
differ
time
presenc
chang
respect
approxim
increas
valu
multipl
viru
growth
cycl
presenc
drug
provid
evid
drug
resist
